Streetbeat News

Regulatory

BNTX

BioNTech shares rose after the FDA allowed the resumption of its partnered Phase 1 trial for BNT326/YL202.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 3:15 pm

GSAT

Globalstar shares rose following the announcement of a 15-year FCC license extension to operate up to 26 replacement satellites.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 3:09 pm

CNI

Canada's Labor Minister is urging railway companies and unions to reach agreements to prevent a full work stoppage. This situation could impact railway operations and related companies.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 2:58 pm

IEP

Carl Icahn and Icahn Enterprises L.P. settled SEC charges for failing to disclose billions in loans backed by Icahn Enterprises stock. The settlement includes $2 million in penalties. Icahn Enterprises shares fell over 7% following the news.

Portfolio Pulse from Adam Eckert

August 19, 2024 | 2:56 pm

LYV

The U.S. Department of Justice has announced that ten additional states have joined a lawsuit against Live Nation Entertainment, Inc. (LYV) and Ticketmaster, accusing them of monopolizing the live concert industry markets.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 2:56 pm

IEP

Hindenburg Research reports that Icahn Enterprises is under SEC investigation for not disclosing margin loan details. The company is accused of operating a Ponzi-like structure, has reported a nearly $1 billion loss, yet continues to pay high distributions and trades at a significant premium. Hindenburg remains short on IEP.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 2:53 pm

IEP

Icahn Enterprises has reported that it has not had any substantive communication with the U.S. Attorney's Office for the Southern District of New York since an initial inquiry on May 3, 2023, according to an SEC filing.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 2:13 pm

JAGX

Jaguar Health has announced a new patent issued in Hong Kong for Napo Pharmaceuticals' Crofelemer, aimed at treating short bowel syndrome and related conditions. The company is also supporting proof-of-concept studies for rare disease indications, with results expected by the end of 2024 and 2025.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 2:07 pm

BTCUSD

ETHUSD

Analyst Alexander Good argues that cryptocurrencies like Bitcoin and Ethereum are gaining acceptance in mainstream financial circles due to geopolitical factors and growing debt concerns. He highlights the interest from influential entities like Bloomberg and Soros Fund as indicators of this shift. Good suggests that the political risk for these cryptocurrencies is overstated, given the support from major institutional players.

Portfolio Pulse from Khyathi Dalal

August 19, 2024 | 1:43 pm

ALZN

Alzamend Neuro Inc. (NASDAQ:ALZN) stock surged after announcing a partnership with Massachusetts General Hospital for a Phase 2 study of AL001 for PTSD treatment. The study aims to assess lithium levels in the brain compared to marketed lithium salts. Alzamend hopes to meet FDA safety standards through the Section 505(b)(2) pathway.

Portfolio Pulse from Vandana Singh

August 19, 2024 | 1:41 pm